A compound represented by formula I or pharmaceutically acceptable salts thereof, wherein R 1 is selected from the group consisting of H and C 1 -C 6 alkyl; R 2 and R 3 are each independently selected from the group consisting of H, C 1 -C 6 alkyl, and C 3 -C 6 cycloalkyl; or R 1 and R 2 , together with the atoms to which R 1 and R 2 are attached, form a 4-7 membered nitrogen-containing heterocyclic ring; m is 1 or 2; preferably, m is 1; n is 0; R 4 and R 5 both are hydrogen or R 4 and R 5 form =O together; preferably, R 4 and R 5 form =O together; is selected from the group consisting of R 6 , R 7 , R 8 , and R 9 are each independently selected from the group consisting of H and C 1 -C 6 alkyl, wherein the C 1 -C 6 alkyl is optionally substituted by halogen; R 10 is H or C 1 -C 6 alkyl, wherein the C 1 -C 6 alkyl is optionally substituted by halogen, OH, or CN; L is an 5-12 membered saturated heterocyclic ring containing 1-2 nitrogen atoms; G is a 6-10 membered aryl optionally substituted by 1-5 R 11 ; R 11 is halogen; with the proviso that neither R 1 nor R 2 is H if R 1 and R 2 , together with the atoms to which R 1 and R 2 are attached, form a 4-7 membered nitrogen-containing heterocyclic ring; preferably, the compound has the structure represented by formula II: preferably, the compound has the structure represented by Formula III: more preferably, the compound has the structure represented by Formula IV: more preferably, the compound has the structure represented by Formula V: more preferably, the compound has the structure represented by Formula VI: wherein, d is 1; more preferably, the compound has the structure represented by Formula VII: wherein, d is 1; preferably, the compound has the structure represented by formula VIII: more preferably, the compound has the structure represented by Formula IX: wherein, d is 1; preferably, the compound has the structure represented by formula XI: more preferably, the compound has the structure represented by Formula XII: wherein, d is 1. R 1 is selected from the group consisting of H and C 1 -C 6 alkyl; R 2 and R 3 are each independently selected from the group consisting of H, C 1 -C 6 alkyl, and C 3 -C 6 cycloalkyl; or R 1 and R 2 , together with the atoms to which R 1 and R 2 are attached, form a 4-7 membered nitrogen-containing heterocyclic ring; m is 1 or 2; preferably, m is 1; n is 0; R 4 and R 5 both are hydrogen or R 4 and R 5 form =O together; preferably, R 4 and R 5 form =O together; is selected from the group consisting of R 6 , R 7 , R 8 , and R 9 are each independently selected from the group consisting of H and C 1 -C 6 alkyl, wherein the C 1 -C 6 alkyl is optionally substituted by halogen; R 10 is H or C 1 -C 6 alkyl, wherein the C 1 -C 6 alkyl is optionally substituted by halogen, OH, or CN; L is an 5-12 membered saturated heterocyclic ring containing 1-2 nitrogen atoms; G is a 6-10 membered aryl optionally substituted by 1-5 R 11 ; R 11 is halogen; with the proviso that neither R 1 nor R 2 is H if R 1 and R 2 , together with the atoms to which R 1 and R 2 are attached, form a 4-7 membered nitrogen-containing heterocyclic ring; preferably, the compound has the structure represented by formula II: preferably, the compound has the structure represented by Formula III: more preferably, the compound has the structure represented by Formula IV: more preferably, the compound has the structure represented by Formula V: more preferably, the compound has the structure represented by Formula VI: wherein, d is 1; more preferably, the compound has the structure represented by Formula VII: wherein, d is 1; preferably, the compound has the structure represented by formula VIII: more preferably, the compound has the structure represented by Formula IX: wherein, d is 1; preferably, the compound has the structure represented by formula XI: more preferably, the compound has the structure represented by Formula XII: wherein, d is 1. <EOS>